Magnetic Nanoparticles in the Imaging of Tumor Angiogenesis
Source abstract
Abstract
Angiogenesis, the growth of new capillary blood vessels, is central to the growth of tumors. Non-invasive imaging of tumor angiogenesis will allow for earlier detection of tumors and also the development of surrogate markers for assessing response to treatment. Steady state magnetic resonance imaging with magnetic nanoparticles is one method to assess angiogenesis. In this article we explain the theory behind steady state magnetic resonance imaging and review the available literature.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Angiogenesis and VEGF in Cancer · Cancer, Hypoxia, and Metabolism · MRI in cancer diagnosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Abdominal Imaging & Interventional Radiology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
Athinoula A. Martinos Center for Biomedical Imaging, 149 Thirteenth St, Suite 2301, Charlestown, MA 02129, USA
References (42)
Show source-provided references
1. Angiogenesis research: From laboratory to clinic
2. Tumorigenesis and the angiogenic switch10.1038/nrc1093 ↗
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis10.1016/S0092-8674(00)80108-7 ↗
4. Role of angiogenesis in tumor growth and metastasis10.1053/sonc.2002.37263 ↗
5. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy10.1126/science.1104819 ↗
6. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors10.1158/0008-5472.CAN-04-0074 ↗
7. Oncotic pressure in solid tumors is elevated
8. Pathology: Cancer cells compress intratumour vessels10.1038/427695a ↗
9. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation10.1038/nm0297-177 ↗
10. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics → mechanism(s) of interaction)10.1007/BF00437479 ↗
11. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy10.2307/3579620 ↗
12. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies10.1093/jnci/81.8.570 ↗
13. Lessons from phase III clinical trials on anti-VEGF therapy for cancer10.1038/ncponc0403 ↗
14. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer10.1056/NEJMoa061884 ↗
15. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study10.1200/JCO.2007.14.9930 ↗
16. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy10.1038/nm0901-987 ↗
17. New immunohistochemical markers in the evaluation of central nervous system tumors: A review of 7 selected adult and pediatric brain tumors10.5858/2007-131-234-NIMITE ↗
18. Angiogenesis in cancer and other diseases10.1038/35025220 ↗
19. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy10.1038/89997 ↗
20. Recent advances in iron oxide nanocrystal technology for medical imaging10.1016/j.addr.2006.09.013 ↗
21. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent10.1002/(SICI)1522-2586(199902)9:2<228::AID-JMRI12>3.0.CO;2-K ↗
22. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice10.1148/radiol.2442060371 ↗
23. Vessel size imaging10.1002/1522-2594(200103)45:3<397::AID-MRM1052>3.0.CO;2-3 ↗
24. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy
25. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice10.1148/radiol.2261012140 ↗
26. MR contrast due to intravascular magnetic susceptibility perturbations10.1002/mrm.1910340412 ↗
27. NMR imaging of changes in vascular morphology due to tumor angiogenesis10.1002/mrm.1910400602 ↗
28. Estimation of tumor microvessel density by MRI using a blood pool contrast agent
29. Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI10.1038/sj.bjc.6604389 ↗
30. The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (DeltaR2*) and contrast agent (MION) dose10.1002/jmri.10371 ↗
31. Vessel size imaging in humans10.1002/mrm.20383 ↗
32. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects10.1002/nbm.1611 ↗
33. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: A longitudinal in vivo and ex vivo study10.1002/nbm.1278 ↗
34. Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI10.1038/jcbfm.2009.86 ↗
35. MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition10.1007/s11307-010-0357-2 ↗
36. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model10.1097/MPA.0b013e31817c5113 ↗
37. Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging10.1097/RLI.0b013e3180d5cbd9 ↗
38. Monitoring of bevacizumab-induced antiangiogenic treatment effects by “steady state” ultrasmall superparamagnetic iron oxide particles magnetic resonance imaging using robust multiecho DeltaR2* relaxometry10.1097/RLI.0b013e3182045457 ↗
39. Nanoparticle imaging of integrins on tumor cells10.1593/neo.05769 ↗
40. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner10.1158/0008-5472.CAN-06-1668 ↗
41. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model10.1096/fj.10-157933 ↗
42. Three-dimensional MR mapping of angiogenesis with α5β1(ανβ3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model10.1096/fj.08-112060 ↗